β cell miRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis

NIH RePORTER · NIH · R01 · $420,806 · view on reporter.nih.gov ↗

Abstract

Type 1 diabetes (T1D) is a chronic metabolic disorder that is characterized by immune-mediated β cell destruction, resulting in the lifelong need for exogenous insulin therapy. Historically, T1D has been considered a disease of β cell homicide. However, recent evidence suggests that the β cell actively contributes to its own demise in T1D through engagement of cell intrinsic stress pathways that both hasten cell death and exacerbate autoimmunity. microRNAs (miRNAs, 18-25 nt) are a class of small non-coding RNAs that post transcriptionally modulate gene expression by binding the 3’untranslated region of a target mRNA to either inhibit mRNA translation or cause mRNA degradation. In addition to these regulatory roles within their cells of origin, miRNAs can be packaged and released within extracellular vesicles (EVs), which can be transferred to recipient cells to both facilitate intercellular communication and promote disease pathogenesis. While miRNAs have been shown to regulate several key processes within the β cell and have been implicated as potential mediators of a dialogue between the immune system and the β cell in diabetes, a full understanding of the role of miRNAs in T1D pathophysiology remains elusive. To this end, we profiled changes in miRNA expression patterns in human islets and islet-derived extracellular vesicles (EV’s) in response to IL-1β and IFN-γ, two cytokines selected to model the inflammatory intra-islet milieu observed in T1D. Our initial small RNA sequencing and additional preliminary data has shown that islet miRNA expression patterns are responsive to inflammatory extrinsic cues and that miRNAs appear to be selectively packaged into islet-derived EV’s in response to cytokine treatment. Moreover, islet and islet-derived EV miRNAs exhibited striking sexually dimorphic expression patterns under basal conditions and following cytokine treatment. Interestingly, miR-155-5p and miR-146-5p were the only two miRNAs that were coordinately upregulated in cytokine-treated islets and islet-derived EVs from both male and female donors, and upregulation of these miRNAs was associated with detrimental changes in β cell function and survival. Based on these findings, we hypothesize that β cell miR-155-5p and miR-146-5p function as key molecular hubs during the evolution of T1D, playing a role in disease pathogenesis, while also having potential utility as diabetes biomarkers. To test this hypothesis, we aim to: 1) define how miRNA signatures change in human β cells during T1D progression using state-of-the art smFISH imaging approaches, focused on miR-155 and 146 and a panel of additional miRNAs predicted to have either common or distinct expression patterns in males and females; 2) elucidate the mechanisms underlying miR-155-5p and miR-146-5p upregulation under inflammatory conditions; 3) define how miR-146 and miR-155 regulate β cell function and survival, leveraging both ex vivo human islet models and novel mouse models of β cell sp...

Key facts

NIH application ID
10111836
Project number
1R01DK127308-01
Recipient
INDIANA UNIVERSITY INDIANAPOLIS
Principal Investigator
Carmella Evans-Molina
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$420,806
Award type
1
Project period
2021-05-01 → 2025-04-30